Safety and efficacy of live attenuated vaccine in patients received hematopoietic stem cell transplantatio
Not Applicable
- Conditions
- Recipients of hematopoietic stem cell transplantation
- Registration Number
- JPRN-UMIN000016500
- Lead Sponsor
- Fukkuoka Blood and Marrow Transplantation Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patient who received immunosuppressive medications. 2. History of malignant tumors. 3. Severe uncontrolled psychiatric disorder or illness. 4. Serious concurrent uncontrolled medical disorders (hepatic dysfunction, renal failure, cardiac dysfunction, pulmonary dysfunction, diabetes, hypertension and infectious diseases). 5. Pregnant or lactating female. 6. Unwillingness or inability to follow the procedures required in the protocol.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Titers of antibody against measles, rubella, mumps and VZV in HSCT patients after vaacination
- Secondary Outcome Measures
Name Time Method Safety of live attenuated vaccine in HSCT patients